Target intelligence / Profile preview

S-layer protein A (SlpA)

Target
SlpA
Molecular classification
Other (Surface layer protein), Structural protein
01

Overview

S-layer protein A (SlpA) is the principal component of the S-layer (surface layer) in various Gram-positive bacteria, notably Clostridioides difficile and Lactobacillus acidophilus. The S-layer is a two-dimensional crystalline protein sheet that completely covers the cell surface, providing physical protection, structural stability, and mediating interactions with the host and environment[1][2][3]. In C. difficile, SlpA is post-translationally cleaved to generate high and low molecular weight subunits that reassemble at the cell surface, forming a tightly packed lattice with molecular sieving properties and acting as the main adhesion and immune evasion factor[2][3][5]. SlpA is essential for bacterial physiology, pathogenicity, and serves as a receptor for bacteriophages[4]. Targeting SlpA disrupts pathogen survival, underlies phage resistance/susceptibility, and offers a promising, but challenging, avenue for novel anti-infective therapeutics and vaccine design[5].

Other names
Surface layer protein AS-layer protein (strain-specific: C. difficile, L. acidophilus)SlpA S-layer protein
02

Mechanism of action

Inhibition or disruption of SlpA impairs pathogen adhesion, surface protection, and makes bacteria susceptible to immune defenses and phage attack - Antibodies or inhibitors can block assembly or expose bacteria to lysis

03

Biological functions

Structural barrier and protectionHost-pathogen interactionAdhesionPhage receptorMolecular sievingImmune evasion
04

Disease associations

Infection (notably in Clostridioides difficile infection, CDI)Inflammatory diseases (indirect, in probiotics from Lactobacillus)
05

Safety considerations

Targeting SlpA may lead to rapid bacterial evolution of antigenic variationPotential off-target effects on commensal bacteria with S-layersDisruption may risk release of endotoxins or other cell wall components
06

Interacting drugs

None currently approved; research targeting SlpA for anti-infective therapies, vaccines, and phage therapies
07

Biomarkers

Expression of SlpA can serve as a marker for C. difficile and potentially for other S-layer expressing bacteria

Beyond the preview

Go deeper on S-layer protein A (SlpA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-layer protein A (SlpA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call